The specialized endocrine and exocrine cells of the pancreas originally derive from a pool of apparently identical cells in the early gut endoderm. Serial changes in their gene expression program, controlled by a hierarchy of pancreatic transcription factors, direct this progression from multipotent progenitor cell to mature pancreatic cell. When the cells differentiate, this hierarchy of factors coalesces into a network of factors that maintain the differentiated phenotype of the cells. As we develop an understanding of the pancreatic transcription factors, we are also acquiring the tools with which we can ultimately control pancreatic cell differentiation. q
Introduction
The pancreas presents a fascinating problem for those interested in the question of how cell fate choice is established during organogenesis. Starting from a pool of apparently identical progenitor cells, the embryonic pancreas transforms into a mature organ containing three clearly distinct cell types: exocrine cells, endocrine cells and duct cells (Edlund, 2001 (Edlund, , 2002 Slack, 1995) . In addition, the endocrine compartment, the islets of Langerhans, further differentiates into four pancreatic endocrine cell subtypes (a, b, d and PP) that have obvious similarities and express common genes -those involved in the regulated secretion of hormones from intracellular vesicles, for example -yet exhibit distinct control over the expression of the exclusive hormones (glucagon, insulin, somatostatin and pancreatic polypeptide, respectively) that they secrete.
It is ultimately regulation at the level of gene transcription that provides the mature pancreatic cells with their unique phenotypes. Therefore the initiation and maintenance of distinct gene expression programs are required to establish the distinct cell types in the pancreas. The development of the mature gene expression program must be a dynamic process of serial changes as cells advance from uncommitted precursor to mature, terminally differentiated cells. This evolution of the gene expression program can be observed as changes in the key players that control the process, the transcription factors, and can be envisioned as a hierarchy or cascade of factors. Eventually, what initially transpires as serial regulation of specific transcription factors goes on to coalesce into the network of transcription factors that define and maintain each differentiated cell phenotype.
Simply cataloguing the transcription factors expressed throughout pancreas development, however, is not particularly informative without delineating how they and their downstream targets act to drive the differentiation process. Ultimately, mouse genetics is the best, although not always the most practical, method for testing the position and function of genes in the transcriptional hierarchy. This approach has yielded a wealth of information about endocrine development over the past few years, and with the advent of techniques that allow more precise engineering of gene expression in the mouse, combined with the technology to look at expression dynamics of large numbers of genes, it is likely that much more can be learned about the integration of the transcription factor cascades that determine pancreatic cell fate.
Why is this important to understand? If we are to understand the mechanisms by which pancreatic cell differentiation occurs, and ultimately control it, we need to understand the pathways through which it proceeds, identify the factors that direct cells along specific differentiation pathways, and understand the interactions among them. Alterations in the relative participation of factors in this network, caused by environment, injury or genetic variation, may precipitate events that contribute to pancreatic disease, such as the beta-cell failure seen in type 2 diabetes. So, identifying the www.elsevier.com/locate/modo hierarchy of transcriptional regulation that controls pancreatic cell differentiation and maintains the mature cell phenotype may allow us to both understand the pathology of betacell failure, and give us the tools to restore beta-cell function.
Starting backwards: cell-type specific transcription in the mature pancreatic cells
While it is convenient to look at the differentiation process as a linear cascade of genes being induced and repressed, the reality is more complicated. The final transcription factor network in a mature cell forms from the intersection of multiple interacting pathways. One of the confounding difficulties with studies that attempt to elucidate these pathways is the fact that most of the factors involved in pancreatic development are expressed at more than one time point and play more than one role. Then in mature cells, the gene expression program becomes an interlocking network of cooperative transcriptional control that maintains the functional phenotype of the cell. As a result, insights into the gene expression program at one stage of differentiation are generally not applicable at other stages.
Nevertheless, working backwards starting from the mature pancreatic cells, the study of how the expression of particular genes is restricted to specific pancreatic cell types, using as examples the islet hormone and exocrine enzyme genes, led to the identification of a host of transcription factors from diverse families, many of which also direct the differentiation of the endocrine and exocrine cells from progenitor cells during embryonic development (Edlund, 1998; Ohneda et al., 2000a; Schwitzgebel, 2001 ). Fig. 1 shows some of the factors known to interact with the regulatory regions of the insulin and glucagon gene promoters. Developmentally important factors originally identified due to their interactions with the insulin gene promoter include isl1, PDX1, and neuroD1 (also called BETA2) (Karlsson et al., 1990; Naya et al., 1995; Ohlsson et al., 1993) . Glucagon promoter function also depends upon developmentally important factors including pax6 , homeobox factor cdx2/3 (Andersen et al., 1999; Hussain and Habener, 1999; Jin et al., 1997) and the forkhead family members Foxa1 and Foxa2 (previously known as HNF3a and b) (Kaestner et al., 1999; Philippe et al., 1994; Shih et al., 1999) . The observation that many of these factors are important in the expression of a broader set of cell-type specific genes, such as the role of PDX1 in the expression of the beta-cell genes islet amyloid polypeptide (Watada et al., 1996a) , glucose transporter 2 (Waeber et al., 1996) , and glucokinase (Watada et al., 1996b) , underlines the role of these factors in the generation of the broader gene expression program that defines the differentiated phenotype of the mature cell.
The pancreatic islet cells, with their ability to sense nutrient changes and respond with vesicular secretion of bioactive peptides, seem to have more in common with neuronal cells than with their neighboring exocrine and ductal cells. Supporting this observation, pancreatic endocrine cells express many genes originally described in neurons, such as tyrosine hydroxylase, neuron-specific enolase and glutamic acid decarboxylase (Bishop et al., 1982; Okada et al., 1976; Teitelman et al., 1981) . It was therefore not surprising to find that pancreatic endocrine development utilizes many transcription factors originally described in neural development. Examples include the paired homeodomain family members pax4 and pax6 (Dohrmann et al., 2000; Sosa-Pineda et al., 1997; St-Onge et al., 1997) , the NK homeodomain factors nkx2.2 and nkx6.1 (Madsen et al., 1997; Sander et al., 2000; Sussel et al., 1998) and the pro-endocrine bHLH genes neurogenin3 and neuroD1 (Apelqvist et al., 1999; Jensen et al., 2000a; Naya et al., 1997; Schwitzgebel et al., 2000) . Conversely, genes identified originally as islet transcription factors have been found to play roles in neuronal development, an example being isl1, which is required for the production of motor neurons as well as playing a role in pancreas development (Ahlgren et al., 1997; Pfaff et al., 1996) .
Despite the functional similarities between the endocrine pancreas and the cells of the nervous system, it has been established that pancreatic endocrine cells are derived from the embryonic endoderm, not the ectoderm from which neurons derive (Fontaine and Le Douarin, 1977; Le Douarin, 1988; Pictet et al., 1976) . Many of the transcription factors involved in the formation, patterning and differentiation of endoderm and its derivatives have been identified (reviews, this issue). Some of these factors have also been shown to be important in the developing pancreas. In particular, a variety of hepatocyte nuclear factors (HNF's), identified originally as regulators of liver specific gene transcription, have been shown to be involved not only in liver organogenesis, but also in the development and function of the pancreas. Thus, the formation of the pancreatic endocrine cells can be viewed as a product of the concerted contributions of at least two groups of factors shared, respectively, with neurons and endoderm tissues including hepatocytes.
Pancreatic bud formation
By embryonic day 8.5 (E8.5) in the mouse, 24 h before the dorsal pancreatic bud first appears, cells in the endoderm in the region of the foregut/midgut junction are already committed to a pancreatic fate, as demonstrated by their unique ability to differentiate into all pancreatic lineages in vitro (Wessells and Cohen, 1967) . This early prepancreatic endoderm selectively expresses two homeodomain transcription factors, the parahox factors PDX1 (Ahlgren et al., 1996; Guz et al., 1995; Offield et al., 1996) and HB9 (Harrison et al., 1999; Li et al., 1999) . The patterning represented by the expression of these factors depends on instructive signals from adjacent tissues (see reviews in this issue and Edlund, 2002; Kim and Hebrok, 2001 ). Competence to respond to the instructive signals is presumably provided by factors that are expressed more broadly in the endoderm and precede PDX1 and HB9, including several transcription factors that were originally described in the adult liver, hepatic nuclear factors 1b (a POU-homeodomain factor) (Ott et al., 1991) , 3a and b (forkhead factors now known as Foxa1 and Foxa2) (Monaghan et al., 1993) , 4a (an orphan nuclear receptor) (Duncan et al., 1994; Taraviras et al., 1994) and 6 (a cut-homeodomain factor) (Landry et al., 1997; Rausa et al., 1997) , and the zinc-finger transcription factors GATA4, 5, and 6 (Arceci et al., 1993; Laverriere et al., 1994) . The hierarchy of these genes in endoderm development has been reviewed previously (Cereghini, 1996; Zaret, 1999 Zaret, , 1996 , although the hierarchy may be somewhat different in the developing pancreas (Boj et al., 2001; ). Several of these endoderm factors have been directly implicated in the control of PDX1 expression (see Fig. 5 ).
Studies of the pdx1 gene promoter have been used to look for factors that control its expression and therefore that may lie upstream of PDX1 in pancreatic development (BenShushan et al., 2001; Gerrish et al., 2001 Gerrish et al., , 2000 Marshak et al., 2001; Samaras et al., 2002; Sharma et al., 1997; Stoffers et al., 1999; Wu et al., 1997) . Most of these studies have been performed in differentiated beta-cells, however, and their conclusions may not apply to the expression of PDX1 in the early pancreatic endoderm. pdx1 (4.3 kb) upstream sequence can recapitulate endogenous PDX1 expression in transgenic mouse embryos (Stoffers et al., Fig. 2 . Mouse pancreatic buds at E10.5. In (A), nuclei expressing Foxa2 are stained red. In (B), nuclei expressing PDX1 are stained red. Glucagonproducing cells are shown in green in both panels. DP, dorsal pancreatic bud; VP, ventral pancreatic bud; PD, proximal duodenum; DD, distal duodenum; L, liver. 1999; Wu et al., 1997) and conserved regions have been identified that can direct expression in early pancreatic epithelium or in the mature islet (Samaras et al., 2002; Stoffers et al., 1999; Wu et al., 1997) . Among the factors that bind to these important sequences are members of the HNF1 and Foxa families of transcription factors, the paired homeodomain factor pax6, and PDX1 itself (Gerrish et al., 2000; Marshak et al., 2000; Sharma et al., 1997; Wu et al., 1997 ) (HB9 may also bind to these same PDX1-binding sites, given its similarity to PDX1 in the DNA-binding homeodomain). HNF1a and pax6 are not expressed early enough or broadly enough to initiate the early expression of PDX1 in the embryonic gut and pancreatic buds, but the expression patterns of HNF1b, Foxa1, and Foxa2 suggest that they could play this role (see Fig. 2 ). Mice null for Foxa2 or HNF1b (Ang and Rossant, 1994; Coffinier et al., 1999b; Weinstein et al., 1994 ) die before pancreas formation, but embryoid bodies lacking Foxa2 fail to activate the pdx1 gene, suggesting that Foxa2 may be a bona fide activator of PDX1 expression in the prepancreatic endoderm and pancreatic buds and therefore lie directly upstream of PDX1 in the hierarchy of factors involved in initiating pancreas development (Gerrish et al., 2000) .
Once expressed, PDX1 plays a critical role early in pancreas formation (Hui and Perfetti, 2002; McKinnon and Docherty, 2001) . As the dorsal and ventral pancreatic buds start to form, expression of PDX1 persists in the undifferentiated pancreatic epithelium, and also in the adjacent duodenum and antral stomach (Ohlsson et al., 1993; Peshavaria et al., 1994) . Broad expression continues in the undifferentiated epithelial cells of the pancreatic buds until E13 when it becomes restricted, with low expression remaining in some duct and exocrine cells and enhanced expression in most beta-cells and some delta cells. Removal of PDX1 by gene targeting arrests pancreatic development after initial bud formation, resulting in an animal with no pancreas (Ahlgren et al., 1996; Jonsson et al., 1994; Offield et al., 1996) . A homozygous mutation in the IPF1 gene, which encodes human PDX1, was identified in a human patient with similar pancreatic agenesis (Stoffers et al., 1997b) , and mutations in the zebra fish gene encoding PDX1 also affect pancreas development (Yee et al., 2001) , reflecting an evolutionary conservation of PDX1 function.
The phenotype of mice lacking PDX1 demonstrates that PDX1 is necessary for the growth of the pancreatic buds but not for the initial induction of bud formation. Interestingly, ectopic expression of PDX1 in non-pancreatic regions of gut endoderm in chick embryos can induce evagination of the gut epithelium similar to pancreatic bud formation (GrapinBotton et al., 2001) , suggesting that PDX1 may play a sufficient, but redundant, role in pancreatic bud induction.
In contrast, HB9 is necessary for bud induction, but only for the dorsal bud. Expression of HB9 precedes PDX1 in the dorsal prepancreatic endoderm, and commences simultaneously with PDX1 in the ventral prepancreatic endoderm . HB9 is down regulated when the pancreatic buds form but reappears in the differentiated beta-cells. In embryonic mice homozygous for targeted mutations in the Hlxb9 gene that encodes HB9, the dorsal prepancreatic endoderm fails to express PDX1 and formation of the dorsal pancreatic bud never initiates (Harrison et al., 1999; . This intriguing phenotype demonstrates that HB9 functions upstream of PDX1 in the dorsal, but not the ventral pancreatic bud, and adds to a body of evidence that different sets of factors control dorsal and ventral pancreatic specification.
To understand how HB9 and PDX1 drive the formation and growth of the pancreatic bud, it will be important to identify the downstream gene targets of these transcriptional regulators. PDX1 was originally identified as a transactivator of the insulin and somatostatin gene promoters (Leonard et al., 1993; Miller et al., 1994; Ohlsson et al., 1993) , and has been implicated in the expression of a number of genes in differentiated beta-cells, including the glucose transporter glut2, glucokinase, and islet amyloid polypeptide (Chakrabarti et al., 2002; Macfarlane et al., 2000; Waeber et al., 1996; Watada et al., 1996a,b) . Unfortunately, however, with the possible exception of pax4 (Chakrabarti et al., 2002; Smith et al., 2000) , no gene targets of PDX1 in the prepancreatic endoderm or the early pancreatic buds have been identified.
Transcription factors exert their effects on a particular promoter as part of a complex of DNA and non-DNA binding proteins that act in concert to stabilize and activate the RNA pol II complex on the promoter (Carey, 1998) . In binding to target genes, PDX1 physically interacts with a variety of other nuclear proteins (Asahara et al., 1999; Dutta et al., 2001; Ohneda et al., 2000b; Peers et al., 1995; Qiu et al., 2002) including another homeodomain factor, Pbx1 (Asahara et al., 1999; Dutta et al., 2001; Peers et al., 1995) . Pbx family members are widely expressed throughout the developing embryo as well as the pancreas, and dimerize with a variety of hox and parahox homeodomain transcription factors (Chan et al., 1994; Chang et al., 1995; van Dijk and Murre, 1994) , thereby modulating both their DNA-binding specificity and function. In the absence of Pbx1, the development of both the endocrine and the exocrine pancreas is impaired in a pattern that partially replicates the defects seen in PDX1 null embryos (Kim et al., 2002 ). An elegant experiment by Dutta et al. demonstrated that the role of Pbx1 in the pancreas is tied to its ability to interact with PDX1, since removal of the domain of PDX1 that interacts with Pbx1 prevents a PDX1 transgene from fully rescuing pancreas development in pdx1 2/2 animals (Dutta et al., 2001) . Like PDX1 itself, PDX1/Pbx1 complexes are necessary for the expansion of the pancreatic buds but not for the specification of the different pancreatic cell types.
Endocrine and exocrine specification
Endocrine and exocrine specification in the pancreas can be viewed as a process of determining which cells out of a large pool of apparently uniform precursors will eventually differentiate into mature islet or acinar cells. The precursor pool is in the form of convoluted sheets of epithelial cells that make up the early pancreatic buds. Since the early pancreatic epithelium uniformly expresses PDX1 and HB9, other factors must determine the subsets of cells that will become endocrine or exocrine cells. Furthermore, the genetic studies that implicate PDX1 and HB9 in bud formation and outgrowth do not support an essential role for these factors in the specification of the different pancreatic lineages, since cells of distinct lineages can differentiate in the absence of either factor (Ahlgren et al., 1996; Harrison et al., 1999; Li et al., 1999; Offield et al., 1996) .
In many ways, the specification of the endocrine cells in the developing pancreatic endoderm is reminiscent of the process by which neurons are specified in the developing neuroectoderm. In a field of initially identical cells in the neuroectoderm, the cells that first initiate the neural differentiation program inhibit neural differentiation in their neighbors through the notch signaling pathway, thereby forcing them to remain as precursors and eventually assume an alternate cell fate (Lewis, 1998) . In this system, notch signaling represses the default activation of the neural differentiation program in most of the cells in the field, limiting neural differentiation to a subset of cells scattered across the neuroectoderm. In those cells that suppress neurogenesis, the target of notch signaling is a family of genes encoding inhibitory basic helix-loop-helix (bHLH) transcription factors, the hairy/enhancer-of-split (HES) genes. Once activated by notch signaling, the HES factors in turn inhibit the pro-neuronal bHLH genes that otherwise would activate the neural differentiation program (Jan and Jan, 1993; Lee, 1997a) .
In an entirely analogous fashion, notch signaling determines which cells in the developing pancreas will activate the endocrine differentiation program (Apelqvist et al., 1999; Edlund, 2001; Jensen et al., 2000b) . HES-1, the downstream target of notch signaling in the pancreas, inhibits the expression of the pro-endocrine bHLH transcription factor neurogenin3 (Jensen et al., 2000b; Lee et al., 2001 ), a member of the larger neurogenin/neuroD family of vertebrate pro-neuronal genes (Gradwohl et al., 1996; Lee, 1997a; Ma et al., 1996; Sommer et al., 1996) . Neurogenin3 is expressed only briefly in scattered cells in the pancreatic epithelium, and not in differentiated endocrine cells (Apelqvist et al., 1999; Jensen et al., 2000a; Schwitzgebel et al., 2000) ; but lineage tracing using cre recombinase in transgenic animals has demonstrated that these neurogenin3 expressing cells function as endocrine cell precursors . Animals lacking neurogenin3 fail to develop any endocrine cells , while uniform ectopic expression of neurogenin3 throughout the pancreatic epithelium causes massive premature differentiation of the entire pancreas into endocrine cells (Apelqvist et al., 1999; Schwitzgebel et al., 2000) . Together, these studies demonstrate that neurogenin3 expression, permitted by an absence of notch signaling, is both necessary and sufficient for initiating endocrine differentiation in the pancreas.
Notch signaling restricts neurogenin3 to scattered cells within the pancreatic epithelium, but positive signals, permissive and inductive, must initiate neurogenin3 expression in the absence of notch signaling. Studies with the neurogenin3 promoter have identified several transcription factors that may play this role. The promoter for neurogenin3 gene is remarkably conserved across species; and, as expected, it contains multiple-binding sites for the HES1 repressor, which potently inhibits the promoter in transient transfections (Lee et al., 2001 ). In addition, however, the promoter contains binding sites for several other transcriptional activators broadly expressed in the endoderm and the pancreatic buds, including HNF1, Foxa and HNF6 (Jacquemin et al., 2000; Lee et al., 2001 ) (see Fig. 3 ).
Genetic evidence in mice supports a role for HNF6 as an upstream activator of neurogenin3 expression. HNF6 is a Cut-homeodomain transcription factor originally identified as a regulator of hepatic genes including Foxa2 (Lemaigre et al., 1993 (Lemaigre et al., , 1996 Rausa et al., 1997; Samadani and Costa, 1996) . HNF6 is initially expressed throughout the pancrea- tic buds, but after birth is excluded from the mature islets (Rausa et al., 1997) . The neurogenin3 promoter contains HNF6-binding sites and can be activated by HNF6 in cultured cells (Jacquemin et al., 2000) . Mice lacking HNF6 have severely reduced neurogenin3 expression in the developing pancreas, and a severely reduced number of endocrine cells with no organized islets at birth (Jacquemin et al., 2000) .
Given its central role in determining the endocrine lineage in the pancreas, it will be important to understand how neurogenin3 functions on a molecular level and to identify its downstream gene targets. In other tissues where bHLH proteins play a prominent role in development, cell-type differentiation is often initiated by a cascade of bHLH proteins (Arnold and Winter, 1998; Cau et al., 1997; Lee, 1997b) . Fitting with this idea of a cascade of bHLH factors, and in keeping with the concept that pancreatic endocrine cells and neurons develop in parallel pathways, neurogenin3 has been shown to activate the promoter for the gene encoding another member of the family of neural pro-neuronal bHLH factors, neuroD1 (see Fig. 3 ). NeuroD1 is expressed slightly later than neurogenin3 during pancreatic development; but, unlike neurogenin3, it persists in the mature islet cells, where it is the predominant member of the neuroendocrine bHLH family, and plays a role in the expression of a number of differentiated endocrine cell products including insulin (Glick et al., 2000; Naya et al., 1995; Ohneda et al., 2000b; Qiu et al., 2002) . Neurogenin3 can bind to and activate the neuroD1 gene promoter, and it can induce ectopic neuroD1 expression in Xenopus embryos (Huang et al., 2000) . In neurogenin3 null embryos, neuroD1 expression in the pancreas is completely lost , while neurogenin3 expression is unchanged in neuroD1 null embryos .
Like neurogenin3, ectopic expression of neuroD1 induces premature endocrine differentiation in the pancreas, demonstrating that neuroD1 is also a pro-endocrine gene . In the absence of neuroD1, pancreatic islet development is severely impaired; but, unlike embryos lacking neurogenin3, differentiated endocrine cells are generated, but are lost at a high rate due to accelerated apoptosis (Naya et al., 1997) . The less severe phenotype of the neuroD1 null mice suggests that other genes downstream of neurogenin3, possibly other bHLH genes, may compensate for the loss of neuroD1, since neurogenin3 expression is unaffected by the loss of neuroD1 in these animals .
While cells expressing neurogenin3 are destined to become endocrine cells, cells in which neurogenin3 expression is extinguished by notch signaling can become part of the exocrine pancreas. Other factors, in particular the bHLH factor p48, are then required to drive these precursor cells to the exocrine fate. P48 was originally identified as a subunit of the PTF-1 complex that drives the expression of exocrine-pancreas-specific genes such as the pancreatic enzymes Rose et al., 2001 ). Mice lacking p48 fail to develop any exocrine pancreas; both acini and the ductal trees are absent, although islets form within the mesenchyme and migrate to the spleen (Krapp et al., 1998) . No factors that may control the expression of p48 have yet been identified, and studies of the gene encoding p48 have not identified cell-type specific control regions .
Taken together, these studies engender a model in which neurogenin3, downstream of HNF6 and other endoderm factors, specifies which cells in the pancreatic epithelium will differentiate into endocrine cells and initiates the differentiation program, at least in part, by activating the expression of neuroD1. At the same time, cells in which the notch signaling pathway has been activated suppress neurogenin3 and can express P48 and differentiate into exocrine cells.
Endocrine cell subtype determination
Once neurogenin3 has been activated in a progenitor cell in the pancreas, that cell is fated to become an endocrine cell, but it can become any one of four possible endocrine cell subtypes, and other factors control this decision. Ectopic expression of neurogenin3 in the early pancreatic bud drives cells to an endocrine fate, but the cells produced are almost exclusively alpha cells . Since we know that during normal pancreatic development neurogenin3 expressing cells are progenitors for all four endocrine cell subtypes , then either the timing or method of ectopic neurogenin3 expression in these transgenic embryos favors the alpha-cell fate, or the alpha-cell fate is the default outcome for cells that express neurogenin3, and additional signals are required to deviate these cells to alternate fates such as beta-cells.
Part of the difficulty in understanding how endocrine celltype fate is determined is that we do not know when it is determined. Based on the early emergence of alpha-cells and the presence of cells coexpressing insulin and glucagon in the early pancreatic buds, a previous model proposed that endocrine cell precursors initially express glucagon before differentiating into one of the other three endocrine cell subtypes (Alpert et al., 1988; Teitelman et al., 1993) . In this model, endocrine cell subtype determination does not occur until after hormone genes are expressed. This model has fallen into disfavor because hormone coexpressing cells are not present during the major period of islet cell neogenesis in the mouse (E13-E16) and because transgenic lineage tracing studies do not support the idea that all islet cells express glucagon at some stage in differentiation (Herrera, 2000; Herrera et al., 1994 Herrera et al., , 1998 .
Instead, subtype fate seems to be determined before hormone genes are activated. We do not know, however, whether that decision is made before, during or after neurogenin3 expression, and therefore also do not know whether neurogenin3 is necessary for expression of the factors that control endocrine subtype fate. The uniform production of alpha cells in response to ectopic neurogenin3 expression suggests that endocrine cell subtype decisions are made independently of neurogenin3 expression. Since we know that few islet cells other than alpha cells are normally generated in the pancreatic buds prior to E13, the early bud may simply lack instructive signals that deviate progenitor cells to non-alphacell fates. Alternatively, the cells may lack the appropriate set of intrinsic factors involved in endocrine cell subtype decisions, and when neurogenin3 is expressed prematurely in these cells, they uniformly adopt an alpha-cell fate.
A number of transcription factors that are expressed selectively in the endocrine lineage in the developing pancreas and that could play a role in endocrine cell subtype fate decisions have been identified. To date, however, no data has convincingly demonstrated that any of these factors are either necessary or sufficient to control endocrine cell fate decisions. These factors all contain homeodomains and can be divided into early factors (pax4, nkx2.2 and nkx6.1) that are coexpressed with neurogenin3 in endocrine progenitor cells and late factors (pax6, isl1, brn4, HB9 and PDX1) that are found in more mature cells.
The paired-homeodomain factor pax4 is expressed selectively in the developing pancreas and is required for the normal development of beta-and delta cells. Pax4 expression in the pancreas crests just before the peak of endocrine cell genesis at E15 and little or no pax4 can be detected in the mature pancreas (Dohrmann et al., 2000; Smith et al., 1999) . Mice homozygous for a targeted deletion of the pax4 gene develop diabetes at birth due to a profound deficiency of beta and delta cells, although the fates of beta and delta-cell precursors are uncertain . Despite its critical role in beta-cell and delta-cell genesis, pax4 by itself is insufficient to drive neurogenin3-expressing precursors to a beta-or delta-cell fate (Grapin-Botton et al., 2001) (S. Smith, D. Scheel and M.S.G., unpublished observations).
Loss of the NK-homeodomain protein nkx2.2 has an equally profound but very different effect on islet cell differentiation. Nkx2.2 is expressed broadly in the pancreatic bud until E13 when it becomes localized to the neurogenin3-expressing progenitor cells (see Fig. 4 ). Unlike pax4, nkx2.2 also persists in many of the mature endocrine cells including all beta-cells. Mice lacking nkx2.2 have a complete absence of insulin-producing cells, and a reduction in alpha-and PP-cells. They develop islets consisting of alpha, delta and PP cells along with a population of unusual endocrine cells that express IAPP and PDX1, markers of beta cells, but lack other markers such as Glut2 and glucokinase. It seems that in the absence of nkx2.2 beta cells are specified but are unable to differentiate fully to mature, insulin-producing cells (Sussel et al., 1998) .
The islets of mice null for nkx2.2 also fail to express the distantly related NK-homeodomain factor nkx6.1. The pattern of nkx6.1 expression in the pancreas is similar to the pattern of nkx2.2 expression except that it is not expressed in non-beta islet cells (Oster et al., 1998; Sander et al., 2000) . The phenotype of mice lacking nkx6.1, however, is more reminiscent of pax4 null animals, as they have a profound, but not complete, defect in beta-cell generation, and do not produce the aberrantly differentiated endocrine cells seen in the nkx2.2 null pancreas (Sander et al., 2000) , although they also lack the defect in delta cells seen in pax4 null animals.
The absence of nkx6.1 expression in the islets of animals lacking nkx2.2 suggests that nkx2.2 lies upstream of nkx6.1 in the beta-cell differentiation pathway (see Fig. 5 ). Two additional pieces of genetic evidence support this conclusion. First, pancreatic nkx2.2 expression is unaffected in mice null for nkx6.1. Second, the pancreatic phenotype of mice with homozygous mutations in both the nkx6.1 and nkx2.2 genes is identical to the phenotype of nkx2.2 homozygous single mutant mice, demonstrating that the loss of nkx6.1 has no effect on beta-cell differentiation in the absence of nkx2.2 (Sander et al., 2000) . In addition, studies of the nkx6.1 gene promoter suggest that nkx2.2 may directly regulate nkx6.1 expression .
The relationship of pax4 to the nkx factors during islet cell differentiation is less clear. Based solely on timing of expression in progenitor cells, it is unlikely that pax4 lies upstream of nkx2.2, although it could lie downstream of nkx2.2 along with nkx6.1. Given their apparently similar roles in the beta-cell differentiation pathway, it will be inter- Fig. 4 . Transcription factor coexpression in mouse pancreas at E15.5. In (A), nuclei containing nkx2.2 are stained red, and nuclei containing neurogenin3 are stained green. Nuclei containing both nkx2.2 and neurogenin3 appear yellow. In (B), nuclei containing neurogenin3 are stained red, and nuclei containing PDX1 are stained green. No cells coexpressing PDX1 and neurogenin3 can be detected.
esting to test the relative positions of nkx6.1 and pax4 in the pathway.
The pax4 gene appears to be a direct target of neurogenin3 (see Fig. 3 ). Neurogenin3 can bind to and activate the pax4 gene promoter (Smith et al., 2000) , it can activate the intact gene in cultured cells (R. Gasa and M.S.G., unpublished observations), and in its absence pax4 expression is lost in the pancreas . In addition, studies of the pax4 gene promoter implicate the more broadly expressed factors HNF1 and HNF4 in cooperative activation of pax4 expression along with neurogenin3 (Smith et al., 2000) .
The late factors pax6, isl1, PDX1 and brn4 function in the final steps of islet-cell differentiation, after neurogenin3 expression and in conjunction with hormone gene expression (see Fig. 5 ). As demonstrated by their roles in the expression of many of the islet hormone genes, these factors are critical to the development and maintenance of the final differentiated islet cell phenotypes. The paired-homeodomain factor pax6 and the LIM-homeodomain factor isl1 are expressed in all islet cells and their loss causes defects in the generation of all endocrine cell subtypes (Ahlgren et al., 1997; St-Onge et al., 1997) . In addition, both factors activate islet hormone gene expression, with pax6 implicated in glucagon, insulin and somatostatin expression , and isl1 implicated in glucagon and somatostatin expression (Leonard et al., 1992; Vallejo et al., 1992; Wang and Drucker, 1995) .
In addition to its early role in bud formation, PDX1 also plays a role in the final differentiation of mature islet cells. After its early expression in the prepancreatic endoderm and early pancreatic buds, PDX1 expression is down regulated.
PDX1 cannot be detected in the neurogenin3 expressing endocrine cell progenitors (Fig. 4) , but its expression is reactivated in most differentiated beta-cells and some delta cells, where it plays a role in maintaining the differentiated phenotype. The expression of a number of mature beta-and delta-cell gene products is regulated by PDX1 (Chakrabarti et al., 2002; Leonard et al., 1993; Macfarlane et al., 2000; Miller et al., 1994; Ohlsson et al., 1993; Waeber et al., 1996; Watada et al., 1996a,b) , and if PDX1 is removed from mature beta-cells by cre-recombinase-mediated deletion, the expression of many of these genes is impaired and beta-cell loss is accelerated (Ahlgren et al., 1996) .
The POU-homeodomain factor brn4 also is activated in mature islet cells, but it is restricted to non-beta-cells, predominantly alpha cells (Hussain et al., 1997; Wilson et al., 2002) , where it regulates glucagon gene expression (Hussain et al., 1997) . Animals null for brn4 do not exhibit any defect in alpha-cell formation (Phippard et al., 1999) . Ectopic expression of brn4, however, produces an interesting phenotype. When driven by the pdx1 gene promoter, brn4 expression gives rise to beta-cells that coexpress insulin and glucagon (Hussain et al., 2002) , demonstrating the importance of the late islet differentiation factors in defining the final differentiated phenotype of the individual endocrine cell subtypes, but not their identity.
Summary
As mouse genetic studies have begun to outline the differ- Lee et al., 1995; Malecki et al., 1999; Mutoh et al., 1998; Naya et al., 1997 Naya et al., , 1995 Qiu et al., 1998 Ahlgren et al., 1996 Ahlgren et al., , 1998 Guz et al., 1995; Jonsson et al., 1994; Offield et al., 1996; PerezVillamil et al., 1999; Schwartz et al., 2000; Stoffers et al., 1997a,b; Waeber et al., 1996; Watada et al., 1996a,b Rudnick et al., 1994; Sander et al., 2000; Sussel et al., 1998; Watada et al., 2000 Nkx6.1 NK-homeodomain b Cells and CNS Decreased b cells, postnatal lethal Jensen et al., 1996; Rudnick et al., 1994; Sander et al., 2000; Sussel et al., 1998 Cdx2/3 Caudal-homeodomain Islet and gut Glucagon Het: gut tumors Hom: Embryonic lethal Chawengsaksophak et al., 1997; German et al., 1992; Jin and Drucker, 1996; Jin et al., 1997; Laser et al., 1996 Isl1 LIM-homeodomain Islet and CNS Somatostatin, glucagon No islet cells, embryonic lethal Het: late onset diabetes Ahlgren et al., 1997; Dong et al., 1991; Karlsson et al., 1990; Leonard et al., 1992; Shimomura et al., 2000; Thor et al., 1991; Vallejo et al., 1992 Lmx1.1 LIM-homeodomain b Cells and CNS Insulin Dreher: roof plate, cerebellum defects German et al., 1992; Millonig et al., 2000; Ohneda et al., 2000b Embryonic lethal Duncan et al., 1998; Gerrish et al., 2000; Lee et al., 2001; Rausa et al., 1997 Rausa et al., , 1998 Rausa et al., , 1999 Sharma et al., 1997; Sund et al., 2001; Wu et al., 1997 Foxa3/HNF3g Forkhead/Winged Helix Islet, gut, liver Glucagon No pancreatic phenotype Kaestner et al., 1994 Kaestner et al., , 1998 Liu et al., 2002 HNF4a Nuclear receptor Liver, islet, kidney HNF1a, glycolytic enzymes, pax4
Embryonic lethal Het: MODY1 Duncan et al., 1994 Miquerol et al., 1994; Sladek et al., 1990; Smith et al., 2000; Yamagata et al., 1996a ent roles of the pancreatic transcription factors, this information along with knowledge of their expression patterns and insights into their molecular function enables us to start placing the factors in a loose hierarchy (Fig. 5) . While clearly this model reduces complicated relationships to an overly simplistic outline, it provides a starting point for thinking about how the gene expression program evolves as cells move from multipotent endodermal progenitors to mature pancreatic cells. The model also provides testable hypotheses regarding the relative positions of individual transcription factors within the different lineages. A number of important questions remain regarding the relative positions of known factors in this scheme, the identity of unknown factors, and how each of the factors controls the expression of the genes downstream of it. One of the key unanswered questions is how and when are the cell fate decisions made that determine which of the specific endocrine cell subtypes the endocrine cell precursors will become? Is this decision made after neurogenin3 expression, and therefore downstream of neurogenin3, or is the decision made independently of neurogenin3? Are individual endocrine cell subtype fates controlled by single factors analogous to the role of neurogenin3 in specifying endocrine cells, or are these decisions orchestrated by an interplay of several factors? Careful analysis of the roles of the known islet differentiation factors and possibly the identification of new players will help answer these questions.
In addition, many of the transcription factors discussed in this review have been found to be mutated in monogenic forms of diabetes (Table 1) , and indeed transcription factors found in Fig. 5 account for five of the six genes known to cause Maturity Onset Diabetes of the Young (MODY) (Horikawa et al., 1997; Malecki et al., 1999; Stoffers et al., 1997a; Yamagata et al., 1996a,b) . In addition, mutations in the coding sequence of isl1 and pax4 have been implicated in families with later onset diabetes (Malecki et al., 1999; Shimomura et al., 2000) . Analysis of these mutations has given insight into the process by which beta-cell dysfunction may lead to the development of diabetes.
Finally, one additional important goal of understanding how cell fate decisions are controlled and organs develop is to apply that understanding to the engineering of cells and tissues for patients. The insights into the mechanisms that control the generation of pancreatic cells during development may eventually be applicable to the development of strategies for tissue regeneration for patients and for replacing the beta cells in patients with diabetes.
